ARO-AAT
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
Oct 31, 2019 → Dec 14, 2023
NCT ID
NCT03946449About ARO-AAT
ARO-AAT is a phase 2 stage product being developed by Arrowhead Pharmaceuticals for Alpha 1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03946449. Target conditions include Alpha 1-Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03946449 | Phase 2 | Completed |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency